CJC-1295
Category 1Also known as: CJC-1295 with DAC, CJC-1295 no DAC, Modified GRF 1-29
Growth Hormone SecretagogueLast reviewed: April 28, 2026
A synthetic analog of growth hormone-releasing hormone (GHRH) that stimulates the pituitary gland to produce more growth hormone. Available with or without a Drug Affinity Complex (DAC) that extends its half-life.
Mechanism of Action
Binds to GHRH receptors on the pituitary gland, stimulating pulsatile release of growth hormone. The DAC version binds to albumin in the blood, extending the half-life from minutes to approximately 6-8 days.
Common Uses
- Growth hormone optimization
- Improved sleep quality
- Fat loss
- Muscle recovery
- Anti-aging protocols
Known Risks
- Water retention
- Tingling or numbness
- Potential cortisol elevation
- Limited long-term safety data
- May affect blood sugar levels
Regulatory Status
Reclassified to Category 1 in February 2026 as part of the HHS announcement restoring compounding access. Not affected by the April 15, 2026 Category 2 removal action. Available through licensed 503A compounding pharmacies with a physician prescription.
Common Protocols
Protocol information is for educational reference only. Dosing varies significantly by individual, condition, and physician guidance. Always work with a licensed healthcare provider.
Subcutaneous injection
Typical Dose
100–300 mcg (no DAC) / 1–2 mg (with DAC)
Frequency
No DAC: 2–3x daily | With DAC: once weekly
Cycle Length
8–12 weeks on, 4 weeks off
Almost always stacked with Ipamorelin. Inject before bed to align with natural GH pulse. No DAC version preferred for more physiological pulsatile release.
Related Compounds
Research References
Related Articles
This information is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting any peptide therapy. Data is compiled from published research and regulatory sources and may not reflect the most recent developments.